Poster Presentations: 

Abstract Title: Integrated Analysis of the Efficacy and Safety of Bardoxolone Methyl in Patients with Alport Syndrome 

Presenter: Bradley Warady, MD, Division of Pediatric Nephrology, Children’s Mercy Kansas City, Kansas City, Missouri, USA

Abstract Publication #: PO1301

Abstract Title: Interim Analysis of the EAGLE Trial: An Open-Label Study to Assess the Long-Term Safety and Tolerability of Bardoxolone Methyl in Patients with Alport Syndrome  

Presenter: Pablo E. Pergola, MD, PhD, Renal Associates PA, San Antonio, Texas, USA

Abstract Publication #: PO1300

Abstract Title: Patient Global Impression of Change in Patients with Alport Syndrome in the CARDINAL Phase 3 Trial. 

Presenter: Glenn M. Chertow, MD, MPH, Division of Nephrology, Department of Medicine, Stanford University School of Medicine, Palo Alto, California, USA.

Abstract Publication #: PO1303

Abstract Title: KIDNEY CODE: A Genetic Testing Program for Patients with Chronic Kidney Disease.   

Presenter: Prasad Devarajan, MD, Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA 

Abstract Publication #: PO1292

Abstract Title: Healthcare Resource Utilization by Patients with Alport Syndrome in the US: A Retrospective Claims Analysis.

Presenter: Baris Deniz, Reata Pharmaceuticals, Plano, Texas, United States.

Abstract Publication #: PO1296

Abstract Title: Characterization of Patients with Alport Syndrome in the United States: A Retrospective Analysis of Medical Claims 

Presenter: Baris Deniz, Reata Pharmaceuticals, Plano, Texas, United States.

Abstract Publication #: PO1295 

Bardoxolone

Bardoxolone is an investigational, once-daily, orally administered activator of Nrf2, a transcription factor that induces molecular pathways promoting the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling.

The U.S. Food and Drug Administration has granted Orphan Drug designation to bardoxolone for the treatment of Alport syndrome and autosomal dominant polycystic kidney disease (“ADPKD”). The European Commission has granted Orphan Drug designation in Europe to bardoxolone for the treatment of Alport syndrome.

In November of 2020 the firm completed the Phase 3 CARDINAL trial of bardoxolone in patients with chronic kidney disease (“CKD”) caused by Alport syndrome. In addition to the CARDINAL Phase 3 study, bardoxolone is currently being studied in FALCON, a Phase 3 study for the treatment of ADPKD, MERLIN, a Phase 2 study for the treatment of patients with CKD at risk of rapid progression, and AYAME, a Phase 3 study for the treatment of diabetic kidney disease that is being conducted by our licensee, Kyowa Kirin Co., Ltd. (“KKC”), in Japan. Bardoxolone treatment produced positive results in the PHOENIX Phase 2 study in patients with CKD caused by ADPKD, IgA nephropathy, focal segmental glomerulosclerosis, and type 1 diabetes. 

Reata Pharmaceuticals, Inc.

Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation.

Reata’s two most advanced clinical candidates, bardoxolone and omaveloxolone, target the important transcription factor Nrf2, which promotes the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. We possess exclusive worldwide rights to develop, manufacture, and commercialize bardoxolone, omaveloxolone  and our next-generation Nrf2 activators, excluding certain Asian markets for bardoxolone in certain indications, which are licensed to KKC.  

Bardoxolone and omaveloxolone are investigational drugs, and their safety and efficacy have not been established by any agency.

Click here to read more about Reata Pharmaceuticals.

See our latest article under Impacting News.